文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

居家护理对接受索拉非尼治疗的肝细胞癌患者的影响。

Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib.

作者信息

Moser Monika, Radu Iuliana-Pompilia, Dufour Jean-François

机构信息

Hepatology, Department of Clinical Research University of Bern Bern Switzerland.

University Clinic for Visceral Surgery and Medicine, Inselspital Bern Switzerland.

出版信息

JGH Open. 2021 Jul 6;5(8):864-870. doi: 10.1002/jgh3.12533. eCollection 2021 Aug.


DOI:10.1002/jgh3.12533
PMID:34386593
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8341184/
Abstract

BACKGROUND AND AIM: Treatment with sorafenib causes diverse side effects, which limits adherence. This work assesses whether Home Care, a psychosocial nursing intervention, prolongs the duration of treatment in patients with advanced hepatocellular carcinoma (HCC) and if it influences health-related quality of life (HRQL). METHODS AND RESULTS: This is a cohort study using data from patients receiving sorafenib in the prospective Bern HCC Cohort at the University Hospital. Duration of treatment, overall survival, and HRQL using the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire were compared in the two groups. A total of 173 patients were eligible for the analysis. Among them, 141 were in the Home Care program, and 32 were not. Patients with Home Care had a significantly longer duration of treatment (265 days 152 days,  = 0.003) and a better functional well-being (17.7 12.5,  = 0.015). CONCLUSION: Psychosocial interventions such as Home Care are a valid method in improving adherence to sorafenib and can therefore be recommended.

摘要

背景与目的:索拉非尼治疗会引发多种副作用,这限制了患者的依从性。本研究评估心理社会护理干预措施“家庭护理”是否能延长晚期肝细胞癌(HCC)患者的治疗时长,以及是否会影响其健康相关生活质量(HRQL)。 方法与结果:这是一项队列研究,使用了大学医院前瞻性伯尔尼HCC队列中接受索拉非尼治疗患者的数据。比较了两组患者的治疗时长、总生存期以及使用癌症治疗功能评估-肝胆问卷得出的HRQL。共有173例患者符合分析条件。其中,141例参与了家庭护理项目,32例未参与。接受家庭护理的患者治疗时长显著更长(265天对152天,P = 0.003),且健康状况良好程度更高(17.7对12.5,P = 0.015)。 结论:诸如家庭护理这样的心理社会干预措施是提高索拉非尼依从性的有效方法,因此值得推荐。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbf9/8341184/27b7049a7185/JGH3-5-864-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbf9/8341184/27b7049a7185/JGH3-5-864-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbf9/8341184/27b7049a7185/JGH3-5-864-g003.jpg

相似文献

[1]
Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib.

JGH Open. 2021-7-6

[2]
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.

Oncologist. 2016-9

[3]
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Lancet Oncol. 2017-10-26

[4]
Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis.

Liver Cancer. 2019-11

[5]
A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015.

Drug Des Devel Ther. 2019-1-22

[6]
Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.

PLoS One. 2020

[7]
Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment.

BMC Cancer. 2016-11-11

[8]
FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance Status.

Liver Int. 2018-2-20

[9]
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.

Adv Ther. 2020-6

[10]
Sorafenib for the treatment of advanced hepatocellular carcinoma.

Health Technol Assess. 2010-5

本文引用的文献

[1]
Health-Related Quality of Life as a Prognostic Factor in Patients After Resection of Hepatic Malignancies.

J Surg Res. 2019-8-14

[2]
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

World J Gastroenterol. 2018-9-28

[3]
Molecular therapies and precision medicine for hepatocellular carcinoma.

Nat Rev Clin Oncol. 2018-10

[4]
New trials and results in systemic treatment of HCC.

J Hepatol. 2018-4-11

[5]
FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance Status.

Liver Int. 2018-2-20

[6]
Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.

Expert Rev Gastroenterol Hepatol. 2017-9-3

[7]
Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease.

Am J Med. 2017-2

[8]
The effectiveness of therapeutic patient education on adherence to oral anti-cancer medicines in adult cancer patients in ambulatory care settings: a systematic review.

JBI Database System Rev Implement Rep. 2015-6-12

[9]
Global cancer statistics, 2012.

CA Cancer J Clin. 2015-2-4

[10]
The adverse effects of sorafenib in patients with advanced cancers.

Basic Clin Pharmacol Toxicol. 2015-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索